Anti-lap antibody variants and uses thereof

A method of treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen binding fragment thereof, a bispecific molecule comprising the antibody or antigen binding fragment thereof or an immunoconjugate comprising the antibody or antigen binding fragment thereof, wherein the antibody or antigen binding fragment thereof specifically binds to LAP and comprises:

• (a) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 110, 120, and 112, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 113, 114, and 115, respectively;
• (b) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 110, 111, and 112, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 113, 114, and 115, respectively;
• (c) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 16, 26, and 18, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 19, 20, and 21, respectively;
• (d) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 54, 55, and 56, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 57, 58, and 59, respectively;
• (e) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 54, 66, and 56, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 57, 58, and 59, respectively:
• (f) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 54, 55, and 68, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 57, 58, and 59, respectively;
• or
• (g) a heavy chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 54, 66, and 68, respectively, and a light chain variable region comprising CDR1, CDR2, and CDR3 regions comprising the amino acid sequences of SEQ ID NOs:
• 57, 58, and 59, respectively.